Most Read Articles
one year ago
Topical pine tar is safe and effective for the treatment of common skin conditions, based on a review.
2 years ago
Disease severity is associated with the presence of Malassezia species on skin of patients with seborrheic dermatitis based on a study.
2 years ago
Hair loss is a common problem for both men and women. Despite the various treatments available, hair loss remains a difficult condition to treat in most people. To gain better insights into the science behind hair loss, an interview was conducted recently with Dr Jia-Wei Liu, member of the European Hair Research Society and Vice President of Research and Development at Legacy Healthcare, Switzerland. The interview focused on hair loss and its management with CG 210TM, a novel botanical hair and scalp essence. 
Dr. Joseph Delano Fule Robles, 5 months ago

Findings of two studies presented recently at the European Cancer Congress 2017 (ECCO 2017) demonstrates the effect of the PD-1 inhibitor, pembrolizumab, against a rare form of melanoma and bladder cancer. 

Biologic therapies pose risk of reactivation in psoriasis patients with chronic HBV infection

20 days ago

The risk for viral reactivation with biologic therapies is negligible in low-risk patients without hepatitis seropositive for hepatitis B or C virus (HBV and HCV, respectively) core antibody, a recent study has found. However, biologic therapies pose a significant risk in patients with chronic HBV infection, stressing the need for antiviral prophylaxis.

Researchers assessed the safety of biologic therapies in psoriasis patients seropositive for HBV or HCV in this retrospective cohort study. They evaluated the clinical and laboratory data of 30 patients undergoing biologic therapy who were seropositive for HBV or HCV, and conducted a systematic review.

In addition, treatment duration and antiviral prophylaxis were recorded. Hepatitis and viral reactivation during therapy were the primary outcomes.

Serology showed past HBV infection in 17 patients, isolated core antibody in eight patients, HCV infection in four patients and chronic HBV infection in one patient. During a mean follow-up of 4.85 years, none of the patients experienced hepatitis or viral reactivation.

In the systematic review of literature, a total of 49 studies were included. These comprised 312 patients followed for a mean of 30.9 months.

Viral reactivation occurred less in patients who were seropositive for core antibody (two out of 175; yearly rate, 0.32 percent) and in those with HCV infection (three out of 97; yearly rate, 2.42 percent) compared with patients with chronic HBV infection (eight out of 40; yearly rate, 13.92 percent). Antiviral prophylaxis were administered in three of these eight patients with reactivated HBV infection.

The study was limited by the analysis of heterogeneous studies that evaluated different biologic therapies, according to researchers.

Editor's Recommendations
Most Read Articles
one year ago
Topical pine tar is safe and effective for the treatment of common skin conditions, based on a review.
2 years ago
Disease severity is associated with the presence of Malassezia species on skin of patients with seborrheic dermatitis based on a study.
2 years ago
Hair loss is a common problem for both men and women. Despite the various treatments available, hair loss remains a difficult condition to treat in most people. To gain better insights into the science behind hair loss, an interview was conducted recently with Dr Jia-Wei Liu, member of the European Hair Research Society and Vice President of Research and Development at Legacy Healthcare, Switzerland. The interview focused on hair loss and its management with CG 210TM, a novel botanical hair and scalp essence. 
Dr. Joseph Delano Fule Robles, 5 months ago

Findings of two studies presented recently at the European Cancer Congress 2017 (ECCO 2017) demonstrates the effect of the PD-1 inhibitor, pembrolizumab, against a rare form of melanoma and bladder cancer.